1. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies
- Author
-
Bernd Weigle, Monica Menzenski, Pankaj Gupta, Sarah Low, Rachel Kroe-Barrett, Kavita Jerath, Sathyadevi Venkataramani, Klaus J. Erb, Rajkumar Ganesan, Darrin Dutcher, Sanjaya Singh, Kristopher Truncali, and Lee Frego
- Subjects
0301 basic medicine ,Bispecific antibody ,Biophysics ,Biochemistry ,03 medical and health sciences ,Thymic Stromal Lymphopoietin ,Antibodies, Bispecific ,Humans ,Medicine ,Molecular Biology ,Cells, Cultured ,Interleukin-13 ,biology ,business.industry ,Antibodies, Monoclonal ,Cell Biology ,Phenotype ,Steroid resistant ,030104 developmental biology ,Epitope mapping ,Cancer research ,biology.protein ,Cytokines ,Antibody ,business ,Epitope Mapping - Abstract
Patients with severe Th2 type asthma often have a steroid resistant phenotype and are prone to acute exacerbations. Current novel therapies have only marginal therapeutic effects. One of the hypotheses for lack of major efficacy in most patients is targeting only one redundant pathway leaving others active. Hence, we have designed and developed novel highly potent bispecific anti-TSLP/IL13 antibodies called Zweimabs (monovalent bispecific) and Doppelmabs (bivalent bispecific) that concurrently inhibits the signaling by these two cytokines.
- Published
- 2018
- Full Text
- View/download PDF